Antiviral Effects of Oleandrin.
作者： Robert A Newman , K Jagannadha Sastry , Ravit Arav-Boger , Hongyi Cai , Rick Matos
DOI: 10.2147/JEP.S273120
关键词: Cardiac glycoside 、 In vitro 、 Coronavirus disease 2019 (COVID-19) 、 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 、 Ebola virus 、 Oleandrin 、 Cytomegalovirus 、 Virus 、 Medicine 、 Virology
摘要: Over the past 15 years, investigators have reported on utility and safety of cardiac glycosides for numerous health benefits including those as treatments malignant disease, stroke-mediated ischemic injury certain neurodegenerative diseases. In addition to those, there is a growing body evidence novel antiviral effects selected glycoside molecules. One unique glycoside, oleandrin derived from Nerium oleander, has been activity specifically against 'enveloped' viruses HIV HTLV-1. Importantly, recent publication presented in vitro oleandrin's ability inhibit production infectious virus particles when used treatment prior to, well after infection by SARS-CoV-2/COVID-19. This review will highlight known present previously unpublished this Ebola virus, Cytomegalovirus, Herpes simplex viruses.
elsevier.com
paperity.org参考文章(81)
Shannon D. Langford, Paul J. Boor, Oleander toxicity: an examination of human and animal toxic exposures Toxicology. ,vol. 109, pp. 1- 13 ,(1996) , 10.1016/0300-483X(95)03296-R
Shailbala Singh, Sachin Shenoy, Pramod N. Nehete, Peiying Yang, Bharti Nehete, Danielle Fontenot, Guojun Yang, Robert A. Newman, K. Jagannadha Sastry, Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity. Fitoterapia. ,vol. 84, pp. 32- 39 ,(2013) , 10.1016/J.FITOTE.2012.10.017
Wilhelm Schoner, Georgios Scheiner-Bobis, Endogenous and Exogenous Cardiac Glycosides and their Mechanisms of Action American Journal of Cardiovascular Drugs. ,vol. 7, pp. 173- 189 ,(2007) , 10.2165/00129784-200707030-00004
A Mahé, S Chollet-Martin, A Gessain, HTLV-I-associated infective dermatitis The Lancet. ,vol. 354, pp. 1386- ,(1999) , 10.1016/S0140-6736(05)76239-5
Salmaan Kanji, Robert D. MacLean, Cardiac Glycoside Toxicity: More Than 200 Years and Counting Critical Care Clinics. ,vol. 28, pp. 527- 535 ,(2012) , 10.1016/J.CCC.2012.07.005
Chun-Ting Su, John T.-A. Hsu, Hsing-Pang Hsieh, Pi-Han Lin, Ting-Chi Chen, Chuan-Liang Kao, Chun-Nan Lee, Sui-Yuan Chang, Anti-HSV activity of digitoxin and its possible mechanisms. Antiviral Research. ,vol. 79, pp. 62- 70 ,(2008) , 10.1016/J.ANTIVIRAL.2008.01.156
Yoshihisa Yamano, Tomoo Sato, Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Frontiers in Microbiology. ,vol. 3, pp. 389- 389 ,(2012) , 10.3389/FMICB.2012.00389
Petr Babula, Michal Masarik, Vojtech Adam, Ivo Provaznik, Rene Kizek, From Na+/K+-ATPase and cardiac glycosides to cytotoxicity and cancer treatment. Anti-cancer Agents in Medicinal Chemistry. ,vol. 13, pp. 1069- 1087 ,(2013) , 10.2174/18715206113139990304
Ana-Monica Pais-Correia, Martin Sachse, Stéphanie Guadagnini, Valentina Robbiati, Rémi Lasserre, Antoine Gessain, Olivier Gout, Andrés Alcover, Maria-Isabel Thoulouze, Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses Nature Medicine. ,vol. 16, pp. 83- 89 ,(2010) , 10.1038/NM.2065
C. B. Wilen, J. C. Tilton, R. W. Doms, HIV: Cell Binding and Entry Cold Spring Harbor Perspectives in Medicine. ,vol. 2, ,(2012) , 10.1101/CSHPERSPECT.A006866